SciClone opens door to China for DC Bead
This article was originally published in Clinica
SciClone Pharmaceuticals has won exclusive rights to market in China the DC Bead chemoembolisation device, developed by UK-based Biocompatibles International, for the minimally-invasive treatment of malignant hypervascular tumours such as primary liver cancer, hepatocellular carcinoma (HCC).
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.